SUMMARYBackground: Somatostatin analogues are the best therapy for controlling the symptoms of malignant carcinoid syndrome. Octreotide acetate given as subcutaneous injection up to three times daily, intramuscular Lanreotide injection given once per 1-2 weeks and monthly intramuscular Sandostatin LAR have demonstrated similar efficacy in short-term studies. Aim: To assess the long-term effect of Sandostatin LAR on the management of patients with malignant carcinoid syndrome. Methods: This was a 3-year retrospective study. Twenty-seven patients were assessed with a median follow-up of 23 months. Thirteen patients were switched from subcutaneous octreotide and 14 patients

SUMMARY BackgroundOctreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long followup are lacking.